WebSep 17, 2024 · CureDuchenne celebrates Dyne Therapeutics’ public offering on the Nasdaq, under the ticker “DYN”. Today’s initial public offering (IPO) will elevate Dyne’s financial position and accelerate Dyne’s lead programs, which includes Duchenne muscular dystrophy. CureDuchenne values companies like Dyne that utilize fundraising tools such … WebSep 16, 2024 · WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases, …
Dyne Therapeutics - Funding, Financials, Valuation & Investors - C…
WebSep 10, 2024 · Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, announced terms for its IPO on Thursday. The … WebSep 16, 2024 · WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases, today announced the pricing of its initial public offering of 12,251,578 lady wray tour
Dyne Therapeutics Announces Presentations on its DM1 and …
WebDyne Therapeutics, Inc. Financial Information: Market Cap: $707.8mil: Revenues: $0 mil (last 12 months) Net Income $-28.2 mil (last 12 months) IPO Profile: Symbol: DYN: Exchange: NASDAQ: Shares (millions): 12.3: Price range: $19.00 - $19.00: Est. $ Volume ... Priced: Quiet Period Expiration Date: Available only to Subscribers: Lock-Up Period ... WebMar 29, 2024 · Get a real-time Dyne Therapeutics, Inc. (DYN) stock price quote with breaking news, financials, statistics, charts and more. ... IPO Date Sep 17, 2024. … WebDec 23, 2024 · After raising $267.7 million in gross proceeds from its September initial public offering, Dyne Therapeutics Inc. signed a lease this month to occupy the entire three-story office and lab building ... lady wrapped in bubble wrap